Vapotherm
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 48.1m | 126m | 113m | 66.8m | 68.7m | 83.0m | 93.9m |
% growth | 14 % | 161 % | (10 %) | (41 %) | 3 % | 21 % | 13 % |
EBITDA | (44.2m) | (38.0m) | (51.0m) | (72.1m) | (32.7m) | (14.5m) | (7.2m) |
% EBITDA margin | (92 %) | (30 %) | (45 %) | (108 %) | (48 %) | (17 %) | (8 %) |
Profit | (51.1m) | (51.5m) | (59.8m) | (113m) | (58.2m) | (45.5m) | (37.2m) |
% profit margin | (106 %) | (41 %) | (53 %) | (170 %) | (85 %) | (55 %) | (40 %) |
EV / revenue | 4.8x | 5.0x | 4.7x | 2.4x | 1.6x | 0.2x | 0.2x |
EV / EBITDA | -5.2x | -16.5x | -10.5x | -2.2x | -3.3x | -1.1x | -2.3x |
R&D budget | 13.4m | 17.0m | 18.4m | 20.8m | 14.2m | - | - |
R&D % of revenue | 28 % | 13 % | 16 % | 31 % | 21 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Series B | |
N/A | $6.6m | Series D | |
N/A | $11.3m | Series E | |
$20.5m | Series F | ||
N/A | $29.0m | Series A | |
$24.0m | Series B | ||
$20.0m | Series C | ||
$30.0m | Series C | ||
$45.0m | Series D | ||
N/A | $56.0m Valuation: $234m 6.6x EV/LTM Revenues -8.6x EV/LTM EBITDA | IPO | |
$52.0m | Post IPO Debt | ||
* | N/A | $23.0m | Private Placement VC |
Total Funding | CAD286m |
Recent News about Vapotherm
EditVapotherm is a medical technology company specializing in advanced respiratory care solutions. The company provides high velocity therapy, a form of non-invasive ventilation (NIV) that offers ventilatory support without the need for a mask. This technology is particularly beneficial for patients who are mask intolerant, providing a more comfortable and effective alternative to traditional methods. Vapotherm's products are used across various patient populations, from adults with chronic obstructive pulmonary disease (COPD) in emergency departments to delicate infants in neonatal intensive care units (NICU). The company serves a wide range of healthcare providers, including hospitals and emergency care facilities, and has treated over 3.3 million patients globally. Vapotherm operates in the medical device market, focusing on respiratory care. Its business model revolves around the sale of its high velocity therapy systems and related consumables, generating revenue through both initial equipment sales and ongoing supply of disposable components. The company is backed by extensive clinical research and is trusted by over 2,200 hospitals worldwide.
Keywords: respiratory care, high velocity therapy, non-invasive ventilation, mask-free, COPD, NICU, emergency care, medical technology, clinical research, hospitals.